| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0079-6123(08)01126-6 |
| P698 | PubMed publication ID | 18929122 |
| P50 | author | Michal Schwartz | Q21264411 |
| P2093 | author name string | Anat London | |
| P2860 | cites work | Modulating the immune system: a vaccine for glaucoma? | Q22305673 |
| Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system | Q24539880 | ||
| Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease | Q24671661 | ||
| Oxidative stress in neurodegeneration: cause or consequence? | Q28275946 | ||
| Caspases: enemies within | Q29547315 | ||
| Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial | Q30881058 | ||
| The relationship between intraocular pressure and visual field progression in glaucoma | Q30997514 | ||
| Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial | Q31113402 | ||
| Proteomic identification of nitrated proteins in Alzheimer's disease brain | Q31144652 | ||
| Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma | Q33187884 | ||
| Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma | Q33222315 | ||
| Protective autoimmunity is a physiological response to CNS trauma. | Q33947118 | ||
| Cellular response to oxidative stress: signaling for suicide and survival | Q34138566 | ||
| Beyond intraocular pressure: neuroprotective strategies for future glaucoma therapy | Q34194014 | ||
| Excitatory amino acids as a final common pathway for neurologic disorders. | Q34321926 | ||
| Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. | Q34418439 | ||
| Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy | Q34486849 | ||
| Targeting protein aggregation in neurodegeneration--lessons from polyglutamine disorders | Q34548624 | ||
| Glutamate neurotoxicity and diseases of the nervous system | Q34560997 | ||
| Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation | Q34628531 | ||
| Is there more to glaucoma treatment than lowering IOP? | Q34712829 | ||
| Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma | Q34734517 | ||
| Glial modulation of retinal ganglion cell death in glaucoma | Q35059644 | ||
| Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells | Q35063857 | ||
| T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies | Q35160575 | ||
| Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease | Q35320917 | ||
| Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences | Q35677091 | ||
| Surgical lowering of elevated intraocular pressure in monkeys prevents progression of glaucomatous disease | Q35777463 | ||
| The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage | Q35957595 | ||
| Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them all? | Q36180444 | ||
| Protective effects of melatonin in experimental free radical-related ocular diseases. | Q36379509 | ||
| The role of oxidative stress in the dysregulation of gene expression and protein metabolism in neurodegenerative disease | Q36399776 | ||
| Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma | Q36440373 | ||
| The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. | Q36522329 | ||
| A century-old debate on protein aggregation and neurodegeneration enters the clinic | Q36628151 | ||
| From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain | Q36629895 | ||
| Glaucoma as a neurodegenerative disease | Q36736043 | ||
| Pharmacological neuroprotection for glaucoma | Q36770323 | ||
| Glutamate in the mammalian CNS. | Q37610496 | ||
| Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage | Q38201300 | ||
| Protective autoimmunity: interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. | Q38330556 | ||
| Neuronal death in glaucoma | Q40827206 | ||
| Molecular basis of glutamate toxicity in retinal ganglion cells. | Q40873212 | ||
| The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia | Q41213517 | ||
| Outcomes of trabeculectomy for primary open-angle glaucoma | Q41428616 | ||
| Caspases: key mediators of apoptosis | Q41760384 | ||
| Biostatistical evidence for two distinct chronic open angle glaucoma populations | Q42620508 | ||
| Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head | Q42635765 | ||
| Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. | Q43517448 | ||
| The tissue-specific self-pathogen is the protective self-antigen: the case of uveitis. | Q44209323 | ||
| Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. | Q44969003 | ||
| Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells | Q45154170 | ||
| Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. | Q45280864 | ||
| T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. | Q46647187 | ||
| Factors influencing optic nerve head biomechanics | Q46774812 | ||
| Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach | Q46868947 | ||
| The use of cyclodialysis to limit exposure to elevated intraocular pressure in rat glaucoma models | Q46986013 | ||
| Activation of NMDA receptors protects against glutamate neurotoxicity in the retina: evidence for the involvement of neurotrophins | Q48215686 | ||
| Glutamate toxicity in chronic neurodegenerative disease. | Q48291440 | ||
| Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: the Friedenwald lecture | Q48357321 | ||
| The role of specific ions in glutamate neurotoxicity | Q48364787 | ||
| Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture | Q48387731 | ||
| Free radical scavenging and inhibition of nitric oxide synthase potentiates the neurotrophic effects of brain-derived neurotrophic factor on axotomized retinal ganglion cells In vivo. | Q48539147 | ||
| Reduced glutamate uptake by retinal glial cells under ischemic/hypoxic conditions. | Q52533903 | ||
| The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. | Q53872479 | ||
| Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. | Q53913933 | ||
| ALS, SOD and peroxynitrite | Q59070047 | ||
| Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis | Q64869641 | ||
| N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina | Q68126319 | ||
| Protective effects of flunarizine on ischemic injury in the rat retina | Q68140166 | ||
| The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease | Q69572781 | ||
| Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis | Q70958165 | ||
| In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection | Q71562869 | ||
| Glutaate-induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion | Q72397927 | ||
| Checkpoints of dueling dimers foil death wishes | Q72790765 | ||
| Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity | Q73098016 | ||
| Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7--2 (CD86) and prevention of cyst formation | Q73727740 | ||
| Potential role for Ginkgo biloba extract in the treatment of glaucoma | Q73735546 | ||
| Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: implications for protective autoimmunity | Q74558134 | ||
| Trafficking of molecules and metabolic signals in the retina | Q77057696 | ||
| Primary open-angle glaucoma | Q80122027 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 375-384 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Progress in Brain Research | Q15800382 |
| P1476 | title | Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation | |
| P478 | volume | 173 |
| Q42647905 | Association of lens vault with narrow angles among different ethnic groups |
| Q37552148 | Associations of sleep duration with open angle glaucoma in the Korea national health and nutrition examination survey |
| Q41489091 | Biomarkers of primary open-angle glaucoma |
| Q38077553 | The immunological basis of degenerative diseases of the eye. |
| Q37809108 | The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential |
Search more.